临床治疗新探索:全反式维甲酸联合小剂量CD20单克隆抗体治疗成人免疫性血小板减少症
New exploration in clinical treatment:All-trans retinoic acid plus low-dose rituximab in the treatment of adult immune thrombocytopenia
张晓辉1
作者信息
- 1. 国家血液系统疾病临床医学研究中心,北京大学人民医院血液病研究所(北京,100044)
- 折叠
摘要
免疫性血小板减少症是一种孤立的血小板减少症,其特点是免疫失耐受介导的血小板破坏增多和血小板生成减少.其治疗包括皮质类固醇、静脉注射免疫球蛋白、利妥昔单抗、血小板生成素受体激动剂、免疫抑制剂和脾切除术.尽管目前的疗法对2/3以上的患者有效,但仍有一些患者无法获得长期疗效.本文介绍了全反式维甲酸联合小剂量CD20单克隆抗体治疗成人免疫性血小板减少症的疗效、安全性以及应用前景.
Abstract
Immune thrombocytopenia is an isolated thrombocytopenia characterized by the increased platelet destruction and decreased platelet production mediated by the loss of immune tolerance.Its treatment includes cor-ticosteroids,intravenous immunoglobulin,rituximab,thrombopoietin receptor agonists,immunosuppressants,and splenectomy.Although current therapies are effective for over two-thirds of patients,there are still some pa-tients who cannot achieve long-term efficacy.This article introduces the efficacy,safety,and application prospects of all-trans retinoic acid combined with low-dose CD20 monoclonal antibody in the treatment of adult immune thrombocytopenia.
关键词
免疫性血小板减少/全反式维甲酸/利妥昔单抗/免疫治疗Key words
immune thrombocytopenia/all-trans retinoic acid/rituximab/immunotherapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据